IVABRADINE

Drug #2340

Ivabradine (ivabradine systemic) is a member of the drug class miscellaneous cardiovascular agents and is used to treat Heart Failure.Ivabradine is a heart rate lowering agent, acting by selective inhibition of the cardiac pacemaker If current that controls the spontaneous diastolic depolarisation in the sinus node and regulates heart rate.

← Previous drug Next drug →

Primary Characteristics

It belongs to C27H37ClN2O5.

Molecular Weight: 505.06 · Solubility in Water: >10 mg/mL · Non-proprietary name: IVABRADINE · pH: 2.

Pharmacokinetics

Distribution: IVABRADINE has a volume of distribution is 100 L. plasma protein binding is 70%.

Elimination: it is metabolised via 40%, plasma half-life is 2 hours, renal excretion is 70 mL/min.

Indications

IVABRADINE is primarily indicated in conditions like Angina.

IVABRADINE is also indicated for secondary conditions like Chronic congestive heart failure.

Contraindications

None recorded.

Dosage

None recorded.

Drug Interactions

Unknown7 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

None recorded.

Warnings / Precautions

Atrial fibrillation: Ivabradine increases the risk of atrial fibrillation; monitor cardiac rhythm. Discontinue use if atrial fibrillation develop. Bradycardia and conduction disturbances: Ivabradine may cause bradycardia, sinus arrest, and heart block; monitor heart rate prior to initiation and with any dosage adjustment. Risk factors for bradycardia include sinus node dysfunction, conduction defects (eg, first- or second-degree AV block, bundle branch block), ventricular dyssynchrony, and use of other negative chronotropes (eg, digoxin, diltiazem, verapamil, amiodarone). Avoid use with verapamil and diltiazem. Avoid use in patients with second-degree AV block (unless a functioning demand pacemaker is present).

Available Brands

None recorded.